TNFRSF17 and plasma cell myeloma: In conclusion, the current study demonstrated that anti-BCMA CAR-modified Vγ9Vδ2 T cells are myeloma-reactive in vitro and in vivo, suggesting them as a potential candidate for tumor immunotherapy against MM.